The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib — UpSwinG

Non-squamous, Non-Small Cell Lung Cancer Clinical Trial

Official title:
UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif®

Status Completed

Clinical Trial Summary

Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated with an EGFR-TKI

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-squamous, Non-Small Cell Lung Cancer

Clinical Trial Details

NCT number	NCT04179890
Study type	Observational
Source	Boehringer Ingelheim
Contact
Status	Completed
Phase
Start date	December 17, 2019
Completion date	July 22, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04750824` - Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
	Completed	`NCT04206787` - The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer
	Completed	`NCT04795245` - Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma